[go: up one dir, main page]

WO2004099366A3 - Context sensitive parallel optimization of zinc finger dna binding domains - Google Patents

Context sensitive parallel optimization of zinc finger dna binding domains Download PDF

Info

Publication number
WO2004099366A3
WO2004099366A3 PCT/US2003/034010 US0334010W WO2004099366A3 WO 2004099366 A3 WO2004099366 A3 WO 2004099366A3 US 0334010 W US0334010 W US 0334010W WO 2004099366 A3 WO2004099366 A3 WO 2004099366A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna binding
zinc finger
binding domains
context sensitive
finger dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/034010
Other languages
French (fr)
Other versions
WO2004099366A2 (en
Inventor
Keith J Joung
Carl Pabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Institute of Technology
Original Assignee
General Hospital Corp
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Institute of Technology filed Critical General Hospital Corp
Priority to US10/532,258 priority Critical patent/US20070178454A1/en
Priority to AU2003304086A priority patent/AU2003304086A1/en
Publication of WO2004099366A2 publication Critical patent/WO2004099366A2/en
Anticipated expiration legal-status Critical
Publication of WO2004099366A3 publication Critical patent/WO2004099366A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods of identifying multi-finger Zf polypeptides that bind to a sequence of interest. Zf polypeptides identified using the methods described herein can have affinity and specificity for their target sites that is superior to those produced by alternative methods.
PCT/US2003/034010 2002-10-21 2003-10-23 Context sensitive parallel optimization of zinc finger dna binding domains Ceased WO2004099366A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/532,258 US20070178454A1 (en) 2002-10-21 2003-10-23 Context sensitive paralell optimization of zinc finger dna binding domains
AU2003304086A AU2003304086A1 (en) 2002-10-23 2003-10-23 Context sensitive parallel optimization of zinc finger dna binding domains

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60/420,485 2002-10-21
US42045802P 2002-10-23 2002-10-23
US46688903P 2003-04-30 2003-04-30
US60/466,889 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004099366A2 WO2004099366A2 (en) 2004-11-18
WO2004099366A3 true WO2004099366A3 (en) 2006-07-20

Family

ID=33436673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034010 Ceased WO2004099366A2 (en) 2002-10-21 2003-10-23 Context sensitive parallel optimization of zinc finger dna binding domains

Country Status (2)

Country Link
AU (1) AU2003304086A1 (en)
WO (1) WO2004099366A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461896B1 (en) 2011-07-15 2023-11-29 The General Hospital Corporation Methods of transcription activator like effector assembly
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
AU2014214719B2 (en) 2013-02-07 2020-02-13 The General Hospital Corporation Tale transcriptional activators
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN113563476A (en) 2013-03-15 2021-10-29 通用医疗公司 RNA-guided targeting of genetic and epigenetic regulatory proteins to specific genomic loci
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
CN106459995B (en) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 CRISPR-related methods and compositions using dominant gRNAs
EP3158066B1 (en) 2014-06-23 2021-05-12 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
KR102455807B1 (en) 2014-10-01 2022-10-18 더 제너럴 하스피탈 코포레이션 Methods for increasing efficiency of nuclease-induced homology-directed repair
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017044843A1 (en) 2015-09-11 2017-03-16 The General Hospital Corporation Full interrogation of nuclease dsbs and sequencing (find-seq)
US9850484B2 (en) 2015-09-30 2017-12-26 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
CN110290813A (en) 2016-10-14 2019-09-27 通用医疗公司 Epigenetically regulated site-specific nucleases
AU2018273968A1 (en) 2017-05-25 2019-11-28 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
US12344850B2 (en) 2019-07-30 2025-07-01 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
EP3812472B1 (en) 2019-10-21 2022-11-23 Albert-Ludwigs-Universität Freiburg A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANDRASEGARAN S.: "Chimeric Restriction Enzymes: What is Next?", BIOLOGICAL CHEMISTRY, vol. 380, 1999, pages 841 - 848, XP008019125 *
CHOCO Y. ET AL.: "In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence", NATURE, vol. 372, 15 December 1994 (1994-12-15), pages 642 - 645, XP003001072 *
HANES J. ET AL.: "Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems", FEBS., vol. 450, 1999, pages 105 - 110, XP002178365 *
WOLFE S. A. ET AL.: "Combining structure-based design with phage display to create new Cy2His2 zinc finger dimers", STRUCTURE, vol. 8, 21 June 2000 (2000-06-21), pages 739 - 750, XP008070579 *

Also Published As

Publication number Publication date
AU2003304086A8 (en) 2004-11-26
AU2003304086A1 (en) 2004-11-26
WO2004099366A2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2004099366A3 (en) Context sensitive parallel optimization of zinc finger dna binding domains
WO2004092219A3 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1789447A4 (en) RNA INTERFERENCE METHOD AND USES
WO2005123780A3 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
ATE480562T1 (en) CHANGE IN FCRN BINDING AFFINITIES OR SERUM HALF-LIFE TIMES OF ANTIBODIES USING MUtagenesis
WO2004033631A8 (en) Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
EP1864998A3 (en) Binding molecules
WO2001049823A3 (en) Assays for detection of bacillus anthracis
WO2004074310A8 (en) Mycobacterial diagnostics
SI1697421T1 (en) Bispecific antibodies
BR0011849A (en) Enhanced lm609 Grafted Antibodies
WO2008022152A3 (en) Optimized antibodies that target cd19
WO2005011376A3 (en) Altered antibodies having improved antigen-binding affinity
WO2003074679A3 (en) Antibody optimization
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2004046306A3 (en) Fully human antibody fab fragments with human interferon-gamma neutralizing activity
WO2003093472A3 (en) Cgrp binding nucleic acids
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2001051669A3 (en) Nucleic acid binding assay and selection method
EP1801208A4 (en) ANTI-A33 ANTIBODIES
DE60031965D1 (en) HIGHLY SENSITIVE DETECTION OF BIOMOLECULES BY "PHAGE DISPLAY"
WO2006033742A3 (en) Engineered antibody fragment that irreversibly binds an antigen
WO2004081029A3 (en) Novel non-invasive marker for liver disease
WO2004027421A3 (en) Adp assay
WO2009045075A3 (en) A monoclonal antibody specific to human embryonic stem cell, a hybridoma secreting the same and a method for detecting or isolating non-differenced embryonic stem cell

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWE Wipo information: entry into national phase

Ref document number: 10532258

Country of ref document: US

Ref document number: 2007178454

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10532258

Country of ref document: US